Cardiovascular

ICONIC-M: Improving CRT outcome with non-invasive cardiac mapping A multicentre randomised controlled study to assess patient response to CRT comparing ECGI map-guided left ventricular lead placement with empirical lead placement. (ICONIC-M)

GO TO STUDY

A register for collecting and measuring outcomes of licensed Anti-Epileptic Drugs and Epilepsy treatments in patients with Epilepsy and Intellectual Disability and/or Pervasive Developmental Disorders (EP-ID Register)

GO TO STUDY

Cancer and neoplasms

Master Protocol Title: A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib - ISA JZ01 Title: Long-Term Safety of Pirtobrutinib in Participants from Study LOXO-BTK-18001 with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non- Hodgkin Lymphoma (J2N-MC-JZNY (ISA: J2N-MC-JZ01))

GO TO STUDY

Blood Cancer and neoplasms

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (KER-050-D301 (RENEW))

GO TO STUDY

PROgnosiS Prediction after Enhanced or CriTical care (PROSPECT)

GO TO STUDY

Blood

Expectations, Lived Experience and Views of a Novel FActor Eight (ELEVATE)

GO TO STUDY

Cancer and neoplasms

BNT327-03 – A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer (BNT327-03)

GO TO STUDY

Musculoskeletal

First-in-human study to assess the safety and feasibility of intra-articular administration of allogeneic engineered gingival fibroblasts (aeGF) in participants with knee osteoarthritis (GF-OA-001)

GO TO STUDY

Cancer and neoplasms

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

GO TO STUDY

Cancer and neoplasms

A Phase 1, open-label, multicenter, dose-escalation and cohort expansion study of OKN4395, a dual antagonist of EP2 and EP4 prostanoid receptors, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors (INVOKE Trial (OKN-4395-121))

GO TO STUDY